Assembly Biosciences (ASMB) vs CytomX Therapeutics (CTMX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Assembly Biosciences (ASMB) has outperformed CytomX Therapeutics (CTMX) over the past year, losing 42.4% versus a loss of 47.7%. Over five years, ASMB leads with a -21.3% price change compared with -69.9% for CTMX. Assembly Biosciences is the larger company by market cap ($454.4 million vs $442.5 million), about 1.0 times the size.
Assembly Biosciences converts more of its revenue into profit, with a net margin of -8.5% versus -22.8%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ASMB | CTMX |
|---|---|---|
| Share price | $22.19 | $2.03 |
| Market cap | $454.39M | $442.55M |
| 1-day change | -1.38% | -0.98% |
| YTD return | -34.75% | -52.35% |
| 1-year return | -42.36% | -47.68% |
| 5-year return | -21.31% | -69.93% |
| P/E ratio (TTM) | 29.59 | — |
| EPS (TTM) | $0.75 | $-0.51 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $72.30M | $76.20M |
| Revenue growth (YoY) | +153.52% | -44.82% |
| Net income (latest FY) | $-6.12M | $-17.37M |
| Operating margin | -16.76% | -29.35% |
| Net margin | -8.47% | -22.79% |
| 52-week high | $39.65 | $8.21 |
| 52-week low | $19.20 | $1.87 |
| Distance from 52-week high | -44.04% | -75.27% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +130.73% | +509.85% |
| Average volume | 309.38K | 4.27M |
| Shares outstanding | 20.48M | 218.00M |
| Employees | 73 | 69 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Assembly Biosciences is more profitable, keeping -8.5 cents of every revenue dollar as net income versus -22.8 cents for CytomX Therapeutics.
- Assembly Biosciences grew revenue faster in its latest fiscal year (+153.52% vs -44.82%).
About Assembly Biosciences
ASMB stock →Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5366 and ABI-1179, which are in Phase 1 clinical studies for recurrent genital herpes; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical study for the treatment of chronic hepatitis delta virus (HDV) infection.
Health Care · Biotechnology: Pharmaceutical Preparations · 73 employees
About CytomX Therapeutics
CTMX stock →CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing potent biologics designed to treat tumor microenvironment.
Health Care · Biotechnology: Pharmaceutical Preparations · 69 employees
ASMB vs CTMX FAQ
Which is bigger, Assembly Biosciences or CytomX Therapeutics?
Assembly Biosciences (ASMB) is larger, with a market capitalization of $454.39M compared with $442.55M for CytomX Therapeutics (CTMX).
Which stock has performed better over the past year, ASMB or CTMX?
ASMB returned -42.36% over the past 12 months, compared with -47.68% for CTMX (price return, excluding dividends). Past performance does not predict future results.
Are Assembly Biosciences and CytomX Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.